Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using The Cancer Genome Atlas data

2015 ◽  
Vol 25 (1) ◽  
pp. 1-7 ◽  
Author(s):  
In-Wha Kim ◽  
Nayoung Han ◽  
Myeong Gyu Kim ◽  
Therasa Kim ◽  
Jung Mi Oh
Keyword(s):  
Lung Carcinoma ◽  
Copy Number ◽  
Cancer Genome ◽  
The Cancer Genome Atlas ◽  
Variability Analysis ◽  
Atlas Data ◽  
Cancer Genome Atlas ◽  
Genome Atlas ◽  
Copy Number Variability

scholarly journals A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas

2021 ◽  
Vol 145 (11) ◽  
pp. 1367-1378
Author(s):  
Minhua Wang ◽  
Pei Hui
Keyword(s):  
Copy Number ◽  
Treatment Strategies ◽  
The United States ◽  
Cancer Genome ◽  
The Cancer Genome Atlas ◽  
Molecular Profile ◽  
Cancer Genome Atlas ◽  
Endometrial Carcinomas ◽  
Genome Atlas

Context.— Endometrial carcinoma is the most common gynecologic malignancy in the United States and has been traditionally classified based on histology. However, the distinction of certain histologic subtypes based on morphology is not uncommonly problematic, and as such, immunohistochemical study is often needed. Advances in comprehensive tumor sequencing have provided novel molecular profiles of endometrial carcinomas. Four distinct molecular subtypes with different prognostic values have been proposed by The Cancer Genome Atlas program: polymerase epsilon ultramutated, microsatellite instability hypermutated, copy number low (microsatellite stable or no specific molecular profile), and copy number high (serouslike, p53 mutant). Objective.— To discuss the utilities of commonly used immunohistochemical markers for the classification of endometrial carcinomas and to review the recent advancements of The Cancer Genome Atlas molecular reclassification and their potential impact on treatment strategies. Data Sources.— Literature review and authors' personal practice experience. Conclusions.— The current practice of classifying endometrial cancers is predominantly based on morphology. The use of ancillary testing, including immunohistochemistry, is helpful in the identification, differential diagnosis, and classification of these cancers. New developments such as molecular subtyping have provided insightful prognostic values for endometrial carcinomas. The proposed The Cancer Genome Atlas classification is poised to gain further prominence in guiding the prognostic evaluation for tailored treatment strategies in the near future.

scholarly journals The Cancer Genome Atlas Predicts the Prognosis of Lung Carcinoma Based on Genes Associated with m6A Methylation

2021 ◽  
Author(s):  
Huanqing Liu ◽  
Tingting Li ◽  
Chunsheng Dong ◽  
Jun Lyu
Keyword(s):  
Lung Cancer ◽  
Survival Rate ◽  
Lung Carcinoma ◽  
Cancer Genome ◽  
The Cancer Genome Atlas ◽  
Predictive Values ◽  
Rna Methylation ◽  
Cancer Genome Atlas ◽  
M6a Rna Methylation ◽  
Genome Atlas

Abstract Lung cancer has become a predominant cause of death in relation with carcinoma worldwide. N6-methylladenosine (m6A) is a common mRNA that is internally modified, which has a pivotal role in mRNA splicing, outputting, localizing, and translating and in identifying stable features. This study evaluated the expression pattern and prognostic value of m6A-related genes in lung cancer. Expression data of lung cancer samples with related clinical information were obtained from The Cancer Genome Atlas (TCGA). Then, R software was used in combination with several corresponding software packages to identify the regulatory factors of m6A RNA methylation with differential expression. Three genes (METTL3, YTHDF1, and FTO) were overexpressed in lung cancer. METTL3 had a low survival rate (P < 0.05). Significant differences in survival rate were observed among the subgroups, which possessed differently expressed m6A levels. Two latent predicting factors (METTL3 and KIAA1429) that met the independent predictive values were selected. M6A RNA methylation modulators may be involved with the malignant progression of lung cancer, and the two selected risk characteristics of m6A RNA methylation regulators may be a potential prognostic biological marker for guiding customized therapies in patients with lung carcinoma.

Sign in / Sign up

Export Citation Format

Share Document